October 15, 2018 / 5:20 AM / a year ago

Roche says breast cancer late-stage study met primary endpoint

ZURICH, Oct 15 (Reuters) - Roche said its Kadcyla, an antibody drug to treat breast cancer, reduced the risk of the disease recurring in patients with HER2-positive early breast cancer in a late-stage study.

The phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent significantly reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer, the Swiss company said in a statement on Monday.

Reporting by Silke Koltrowitz; editing by Thomas Seythal

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below